Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henan Cancer Hospital
• Treatments: Dacarbazine; Epirubicin; Vincristine

Criteria

Inclusion Criteria:

1. Age between 18 to 75 years old (including 18 and 75)

2. Diagnosed as advanced classical hodgkin's lymphoma based on histopathology

3. Subjects must be untreated (Ann Arbor Stage III/IV or Ann Arbor II with B symptoms along with mediastinal big tumor or extranodal changes)

4. No receiving chemotherapy before enrollment

5. Having at least one measurable lesions

6. World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-1

7. Life expectancy no less than 3 months

8. enough main organ function

9. Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study

10. Agreeing to sign the written informed consents

Exclusion Criteria:

1. Diagnosed as nodular lymphocyte predominant lymphoma or grey-zone lymphoma

2. Diagnosed as central nervous system lymphoma

3. usage of immunosuppressants before enrollment and the dose of immunosuppressant used >10mg / day oral prednisone for more than 2 weeks

4. Previously treated with anti-PD-1/PD-L1/PD-L2/CTLA-4

5. Active autoimmune disease

6. Vaccination with anti-tumor vaccine or other immune treatments less than 3 months

7. Serious surgery and trauma less than two weeks

8. Other malignant tumor history or active malignant tumor need be treated

9. Systemic therapy for serious acute/chronic infection

10. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months

11. Active tuberculosis

12. Vaccination with live attenuated vaccine less than 4 weeks

13. HIV-positive, AIDS patients and untreated active hepatitis

14. Researchers determine unsuited to participate in this trial